KOLLTAN PHARMACEUTICALS
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
KOLLTAN PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2007-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.kolltan.com
Total Employee:
11+
Status:
Active
Contact:
203-773-3000
Total Funding:
146 M USD
Technology used in webpage:
IPhone / Mobile Compatible Sectigo SSL Sectigo Domain SSL Network Solutions DNS AdBlock Acceptable Ads Akamai Adobe Dreamweaver Citrix NetScaler Network Solutions Network Solutions Email Hosting
Similar Organizations
Actinium Pharmaceuticals
Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.
Adastra Pharmaceuticals
Adastra Pharmaceuticals provides responsible solutions to advance patient care in oncology.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Advisor
Board_member
Advisor
Advisor
Current Employees Featured
Joseph Schlessinger Founder @ Kolltan Pharmaceuticals
Founder
Lawrence Fritz Executive Chairman, Co-Founder @ Kolltan Pharmaceuticals
Executive Chairman, Co-Founder
2009-01-01
Yaron Hadari Vice President of Research @ Kolltan Pharmaceuticals
Vice President of Research
2008-01-01
Keith Darragh Vice President of Finance & Administration and Treasurer @ Kolltan Pharmaceuticals
Vice President of Finance & Administration and Treasurer
2014-01-01
Arthur Altschul Jr. Co-Founder & Chairman of the Board @ Kolltan Pharmaceuticals
Co-Founder & Chairman of the Board
Founder
Investors List
Fidelity
Fidelity investment in Series D - Kolltan Pharmaceuticals
KLP Enterprises
KLP Enterprises investment in Series D - Kolltan Pharmaceuticals
Deerfield
Deerfield investment in Series D - Kolltan Pharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - Kolltan Pharmaceuticals
Purdue Pharma
Purdue Pharma investment in Series D - Kolltan Pharmaceuticals
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series D - Kolltan Pharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Kolltan Pharmaceuticals
Tichenor Ventures
Tichenor Ventures investment in Series B - Kolltan Pharmaceuticals
Auven Therapeutics
Auven Therapeutics investment in Series B - Kolltan Pharmaceuticals
Elm Street Ventures
Elm Street Ventures investment in Series A - Kolltan Pharmaceuticals
Official Site Inspections
http://www.kolltan.com
- Host name: underconstruction.networksolutions.com
- IP address: 205.178.189.129
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "Kolltan Pharmaceuticals"
Kolltan Pharmaceuticals - Crunchbase Company Profile …
Kolltan Pharmaceuticals, Inc., is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries …See details»
Kolltan Pharmaceuticals, Inc. | LinkedIn
Kolltan Pharmaceuticals, Inc. | 1,361 followers on LinkedIn. Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other ...See details»
Kolltan Pharmaceuticals - Products, Competitors, Financials, …
Kolltan Pharmaceuticals is a clinical-stage company focused on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases (RTKs). ... VGXI is a Contract …See details»
Kolltan Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. Kolltan Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News ... Kolltan Pharmaceuticals has 5 current employee profiles, …See details»
Kolltan Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Kolltan Pharmaceuticals, Inc. of New Haven, CT. Get the latest business insights from Dun & Bradstreet.See details»
Kolltan Pharmaceuticals Inc - Company Profile and News
Company profile page for Kolltan Pharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»
Kolltan Pharmaceuticals - PitchBook
Kolltan Pharmaceuticals General Information Description. Developer of monoclonal antibody drugs. The company is a clinical-stage enterprise focused on discovery and development of drug candidates targeting receptor tyrosine …See details»
Kolltan Pharmaceuticals - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Celldex Therapeutics Completes Acquisition of Kolltan …
HAMPTON, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today it has completed its previously announced acquisition of …See details»
Kolltan Pharmaceuticals CEO, Founder, Key Executive Team, Board …
Explore {Kolltan Pharmaceuticals's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. ... VGXI is a …See details»
Celldex Expands Antibody and Immuno-Oncology Portfolio with …
Nov 1, 2016 Kolltan is working in close collaboration with the laboratory of Kolltan Co-Founder Dr. Joseph Schlessinger, as well as the Yale University medical and scientific community. The …See details»
Celldex Acquires Kolltan, Expands Antibody & Immuno-Oncology …
Nov 2, 2016 Celldex expands antibody and immuno-oncology portfolio with the acquisition of Kolltan Pharmaceuticals. Celldex Therapeutics, Inc. announced that the company has entered …See details»
Yale Startup Kolltan Pharmaceuticals Nets $35M in VC Financing to ...
Kolltan Pharmaceuticals, a cancer therapeutics company founded last year based on scientific discoveries made at Yale University, said last week that it has raised more than $35 million in …See details»
Celldex Therapeutics, Inc. completed the acquisition of Kolltan ...
Nov 28, 2016 Celldex Therapeutics, Inc. entered into definitive agreement to acquire Kolltan Pharmaceuticals, Inc. from Arthur Altschul, Joseph Schlessinger and others for approximately …See details»
Celldex to Acquire Kolltan for Up to $235M - genengnews.com
Nov 2, 2016 Celldex also agreed to pay Kolltan shareholders up to $172.5 million in additional payments tied to achieving development, regulatory, and commercial milestones.See details»
Michael Schmertzler - Member of the Board of Directors
From 2008 to 2012, Michael Schmertzler served as Chief Executive Officer and a director of Kolltan Pharmaceuticals, Inc., a biotechnology company. Since 2001, Michael Schmertzler has …See details»
Cancer R&D stars pitch an $86M biotech IPO for Kolltan Pharma
Sep 15, 2014 Kolltan was founded in 2007 by Yale scientist Joseph Schlessinger and Arthur Altschul, two of the principals behind Plexxikon. Schlessinger and Altschul also worked on …See details»
Drug Details - gisttrials.org
KTN0158 is the second clinical-stage program for Kolltan and is currently in an open-label, dose-escalating Phase 1 clinical trial focused on cancer patients with gastrointestinal stromal tumors …See details»
Arthur Altschul Jr. - Co-Founder & Chairman of the Board
Arthur G. Altschul, Jr., is the co-Founder of Kolltan and Chairman of Kolltan's Board of Directors. Mr. Altschul has worked in money management, investment banking and as a member of …See details»
KTN0182A - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 KTN0182A, Initially developed by Kolltan Pharmaceuticals, Inc., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication ...See details»